| 1 |
Development of a First-in-Class IVIG Glyco-Based Ophthalmic Eye Drop Candidate for Uveitis Treatment |
| rProtein |
Non-infectious Uveitis, Ocular Surface Inflammatory Diseases |
Ocular Innate immune regulatory receptor pathway |
Candidate |
INUS IMMUNE Co., Ltd. |
RS-2026-25503178 |
|
| 2 |
Development of a Novel Multiple Sclerosis Treatment Using the Regulatory T Cell (Treg)-Modulating Peptide KINE-101 |
| rProtein |
Multiple Sclerosis |
**** |
Preclinical |
KINE SCIENCES |
RS-2025-25454784 |
|
| 3 |
Development of a multi-specific target fusion protein for autoimmune disease |
| rProtein |
psoriasis, psoriatic arthritis |
IL-17A, IL-17F and TNFa |
Candidate |
CUROGEN |
RS-2024-00462095 |
|
| 4 |
Candidate Selection of IL-2v-SAFA for the treatment of rare autoimmune disease |
| rProtein |
Systemic Lupus Erythematosus, IBD |
IL-2 |
Candidate |
AprilBio |
RS-2022-00165592 |
|
| 5 |
Generation of hit/lead compounds to treat multiple sclerosis by targeting formyl peptide receptor |
| rProtein |
Multiple Sclerosis |
FPR |
Hit |
Sungkyunkwan University |
HN22C0255 |
|
| 6 |
Topical immunotherapeutic agent for atopic dermatitis : FPR2-selective pro-resolving peptide ligand |
| rProtein |
Atopic dermatitis |
FPR2 |
Phase 1 |
Novacell technology Inc. |
HN21C1061 |
|